Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · November 26, 2022

Effectiveness of RNS60, a Novel Investigational Immunomodulatory and Neuroprotective Agent, for ALS

European Journal of Neurology


Additional Info

European Journal of Neurology
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial
Eur. J. Neurol. 2022 Sep 23;[EPub Ahead of Print], E Beghi, E Pupillo, E Bianchi, V Bonetto, S Luotti, L Pasetto, C Bendotti, M Tortarolo, F Sironi, L Camporeale, AV Sherman, S Paganoni, A Scognamiglio, F De Marchi, P Bongioanni, R Del Carratore, C Caponnetto, L Diamanti, D Martinelli, A Calvo, M Filosto, A Padovani, SC Piccinelli, C Ricci, S Dalla Giacoma, N De Angelis, M Inghilleri, R Spataro, V La Bella, G Logroscino, C Lunetta, C Tarlarini, J Mandrioli, I Martinelli, C Simonini, E Zucchi, MR Monsurrò, D Ricciardi, F Trojsi, N Riva, M Filippi, IL Simone, G Sorarù, C Spera, L Florio, S Messina, M Russo, G Siciliano, A Conte, MV Saddi, N Carboni, L Mazzini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading